Header Logo

Connection

Donald Jensen to Antiviral Agents

Back to Details
This is a "connection" page, showing publications Donald Jensen has written about Antiviral Agents.
Donald Jensen
Connection Strength
8.960
Antiviral Agents
  1. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577.
    View in: PubMed
    Score: 0.632
  2. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
    View in: PubMed
    Score: 0.511
  3. Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49.
    View in: PubMed
    Score: 0.505
  4. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14.
    View in: PubMed
    Score: 0.491
  5. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7.
    View in: PubMed
    Score: 0.460
  6. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
    View in: PubMed
    Score: 0.434
  7. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93.
    View in: PubMed
    Score: 0.422
  8. The FDA, bridging data, and hepatitis C. Hepatology. 2013 Mar; 57(3):875-7.
    View in: PubMed
    Score: 0.405
  9. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 May; 10(5):268-76.
    View in: PubMed
    Score: 0.404
  10. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. Infect Dis Clin North Am. 2012 Dec; 26(4):879-91.
    View in: PubMed
    Score: 0.398
  11. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int. 2012 Feb; 32 Suppl 1:74-8.
    View in: PubMed
    Score: 0.376
  12. A new era of hepatitis C therapy begins. N Engl J Med. 2011 Mar 31; 364(13):1272-4.
    View in: PubMed
    Score: 0.355
  13. Treatment duration for genotypes 2 and 3: still confusing after all these years. J Clin Gastroenterol. 2010 Sep; 44(8):527-8.
    View in: PubMed
    Score: 0.341
  14. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009 Apr 21; 150(8):528-40.
    View in: PubMed
    Score: 0.310
  15. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. Liver Int. 2009 Apr; 29(4):481-2.
    View in: PubMed
    Score: 0.309
  16. Hepatitis C: current and future therapies. Mt Sinai J Med. 2008 Aug; 75(4):405-14.
    View in: PubMed
    Score: 0.295
  17. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
    View in: PubMed
    Score: 0.295
  18. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008 Jun; 23(6):844-55.
    View in: PubMed
    Score: 0.292
  19. Future directions in therapy for chronic hepatitis C. Antivir Ther. 2008; 13 Suppl 1:31-6.
    View in: PubMed
    Score: 0.283
  20. Retreatment of chronic hepatitis C in previous non-responders and relapsers. Expert Opin Pharmacother. 2007 Oct; 8(15):2491-503.
    View in: PubMed
    Score: 0.278
  21. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006 May; 43(5):954-60.
    View in: PubMed
    Score: 0.252
  22. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol. 2005 Sep; 17(9):899-904.
    View in: PubMed
    Score: 0.241
  23. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 07; 36(7):954-62.
    View in: PubMed
    Score: 0.124
  24. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin North Am. 2014 Sep; 28(3):477-99.
    View in: PubMed
    Score: 0.112
  25. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14.
    View in: PubMed
    Score: 0.109
  26. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9.
    View in: PubMed
    Score: 0.098
  27. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008 Oct; 48(4):1033-43.
    View in: PubMed
    Score: 0.075
  28. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci. 2009 Jun; 54(6):1369-72.
    View in: PubMed
    Score: 0.074
  29. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003 Jul; 39(1):106-11.
    View in: PubMed
    Score: 0.052
  30. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012 Dec; 56(6):2398-403.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.